How to Get Lantus in West Virginia

What Insulin Glargine Is and Why It Matters for West Virginia Patients

Insulin glargine is a long-acting, recombinant basal insulin analog that provides a relatively flat, peakless 24-hour insulin profile after subcutaneous injection. The FDA approved the original formulation (Lantus, 100 U/mL) in April 2000, and the concentrated 300 U/mL formulation (Toujeo) in 2015 [1]. Biosimilar versions, including Basaglar and Rezvoglar, carry the same active ingredient and share the same mechanism [2].

West Virginia has one of the highest rates of diagnosed diabetes in the United States. The CDC's 2022 state-level surveillance data placed West Virginia's adult diabetes prevalence at 16.1%, compared to the national average of 11.6% [3]. That gap makes access to basal insulin a direct public-health issue for the state.

Insulin glargine works by binding the insulin receptor, suppressing hepatic glucose output overnight and between meals. The ORIGIN trial (N=12,537, median follow-up 6.2 years) compared insulin glargine to standard care in people with dysglycemia and found that glargine achieved a median HbA1c of 6.2% without increasing cardiovascular events (hazard ratio 1.02 to 95% CI 0.94-1.11, P<0.001 for non-inferiority) [4]. That cardiovascular safety data, published in the New England Journal of Medicine in 2012, remains the foundational long-term evidence for basal insulin use in high-risk patients.

The American Diabetes Association 2024 Standards of Care classify basal insulin as the preferred injectable therapy when oral agents and GLP-1 receptor agonists have not achieved glycemic targets, citing evidence grade A for type 1 and grade B for type 2 [5].

Who Can Prescribe Lantus in West Virginia

Any of four prescriber types can write a legal Lantus prescription in West Virginia. The scope of practice for each category is set by West Virginia Code and the relevant licensing boards.

Medical doctors and osteopathic physicians (MD/DO) hold full prescriptive authority with no restrictions on insulin prescribing. Nurse practitioners in West Virginia practice under independent prescriptive authority after meeting the requirements of the West Virginia Board of Examiners for Registered Professional Nurses [6]. An NP does not need a physician's co-signature to prescribe insulin. Physician assistants may prescribe Schedule II-V controlled substances and non-controlled medications including insulin under a written collaborative agreement with a supervising physician, as governed by the West Virginia Board of Medicine [6].

Telehealth prescribers must comply with the West Virginia Telemedicine Act (WV Code §30-3-13a), which requires establishing a valid patient-provider relationship before issuing a prescription. A synchronous video visit satisfies that requirement for most practices. An asynchronous photo-based visit does not satisfy it for a new patient in West Virginia.

The HealthRX clinical team uses a four-step access framework for West Virginia patients starting insulin glargine:

1. Confirm diagnosis and labs (fasting glucose, HbA1c, CMP, weight) at or before the visit.
2. Choose visit modality (telehealth video or in-person) and confirm the prescriber holds a WV license.
3. Verify insurance or cost pathway before the prescription is sent (see the cost section below).
4. Select dispensing pharmacy based on whether the patient needs 340B pricing, a mail-order 90-day supply, or same-day pickup.

This sequence shortens the average time from "decision to start insulin" to "first injection" to under 48 hours for most telehealth patients, versus the national average of 7-14 days when in-person specialist referral is required [7].

Telehealth Access to Lantus Prescriptions in West Virginia

West Virginia expressly permits telehealth prescribing of non-controlled medications, including insulin. The state followed the 2020 federal PHE telehealth expansion and codified many of those permissions permanently through the 2022 legislative session.

A patient needs three things for a telehealth Lantus visit: a device with video capability, a valid West Virginia address (the prescriber must be licensed in the state where the patient is located at the time of the visit), and the lab results described below. Most telehealth platforms connected to West Virginia pharmacies can route an e-prescription to a local pharmacy or a mail-order pharmacy the same day the visit concludes.

The FDA's current guidance on insulin prescribing via telehealth does not impose additional requirements beyond standard prescribing standards [8]. The prescription must include drug name, concentration (100 U/mL or 300 U/mL), dose in units, frequency, route, quantity, and refills.

Rural West Virginia counties, including McDowell, Mingo, and Logan, have fewer than one endocrinologist per 50,000 residents. Telehealth fills that gap directly. A 2021 study in JAMA Network Open found that patients in rural Appalachian counties who received telehealth diabetes management achieved HbA1c reductions of 1.3 percentage points over 12 months, comparable to urban in-person care [9].

Labs Required Before Starting Lantus in West Virginia

A prescriber cannot safely dose insulin glargine without a baseline metabolic picture. The minimum lab panel before a first prescription is:

Fasting plasma glucose establishes the pre-treatment baseline and is required to calculate a safe starting dose. The ADA recommends a starting dose of 0.1-0.2 U/kg/day for insulin-naive type 2 patients, titrated by 2 units every 3 days until fasting glucose is 80-130 mg/dL [5].

HbA1c confirms the diagnosis, quantifies glycemic burden, and sets the therapeutic target. An HbA1c of 6.5% or higher meets the ADA's diagnostic threshold for diabetes mellitus [5].

Basic metabolic panel (BMP) provides serum creatinine, eGFR, and electrolytes. Renal impairment does not require dose reduction for insulin glargine specifically (it is not renally cleared), but it changes the titration approach and identifies patients at higher hypoglycemia risk [10].

Body weight is required to calculate weight-based dosing. Most telehealth platforms ask patients to self-report weight at the time of the visit; some require a photo of a scale reading for documentation.

Optional but recommended before starting: thyroid-stimulating hormone (TSH) in patients with suspected type 1 or LADA, lipid panel, and urine albumin-to-creatinine ratio (UACR). The ADA 2024 Standards specify UACR screening at diagnosis for all type 2 patients [5].

Labs drawn at a LabCorp or Quest location in West Virginia are typically available within 24-48 hours. Several telehealth platforms have integrated lab-ordering capability that routes orders to a collection site within 10 miles of the patient's ZIP code.

Getting a Lantus Prescription Filled at a West Virginia Pharmacy

Once a prescription is issued, the patient has four primary pharmacy options in West Virginia.

Retail chain pharmacies (Walgreens, CVS, Rite Aid) stock Lantus 100 U/mL SoloStar pens and vials in most WV locations. Availability of Toujeo 300 U/mL may require 24-48 hours notice. Cash price for a 5-pack of Lantus SoloStar pens runs approximately $280-$350 without insurance, though this varies by location.

340B contract pharmacies serve patients who receive care at a federally qualified health center (FQHC) or rural health clinic. West Virginia has 28 FQHC sites as of 2024 [11]. Patients established at an FQHC can receive insulin glargine at 340B-discounted pricing, which reduces the out-of-pocket cost to as low as $35 per month.

Mail-order pharmacies allow 90-day supplies and may reduce per-unit costs. West Virginia law does not restrict mail delivery of insulin. Most major PBM-affiliated mail pharmacies (Express Scripts, OptumRx, CVS Caremark) ship to WV ZIP codes within 3-5 business days for standard shipping.

Licensed 503A compounding pharmacies in West Virginia may prepare insulin glargine preparations for individual patients with a valid prescription when a commercially available product is not accessible or a patient-specific formula is required. The FDA's guidance on compounded biologics draws a distinction between 503A (patient-specific) and 503B (outsourcing facility) compounding; insulin glargine as a biologic is subject to additional scrutiny under the PHSA Section 351 pathway [8]. Patients considering compounded insulin glargine should confirm the pharmacy is licensed by the West Virginia Board of Pharmacy and that the prescribing clinician has documented the medical necessity.

West Virginia Medicaid and Insurance Coverage

West Virginia Medicaid does not currently cover Lantus (insulin glargine 100 U/mL) by brand name on its preferred drug list. The WV Medicaid preferred drug list as of Q1 2025 lists biosimilar insulin glargine products (Basaglar KwikPen) and NPH insulin as preferred basal insulin options [12].

Patients on WV Medicaid who specifically need Lantus (due to physician preference, prior clinical response, or SoloStar pen device training) must obtain a prior authorization. The PA request must document:

• Diagnosis code confirming type 1 or type 2 diabetes mellitus (ICD-10: E10.x or E11.x)
• At least one trial of or contraindication to the preferred biosimilar
• Prescriber attestation of medical necessity
• Most recent HbA1c value

Most commercial insurance plans in West Virginia (including Highmark BCBS WV, The Health Plan, and UnitedHealthcare WV) cover Lantus on Tier 2 or Tier 3 with prior authorization when a preferred biosimilar has not been tried. Tier 3 copays typically run $45-$90 per 30-day supply after deductible.

The Sanofi Insulins Valyou Savings Program offers a $99 monthly cap for Lantus and Toujeo for eligible commercially insured or uninsured patients in all 50 states including West Virginia [13]. Patients who are uninsured and meet income criteria may also qualify for Sanofi's Patient Assistance Program, which provides insulin at no cost.

Transferring an Existing Lantus Prescription to West Virginia

A patient moving to West Virginia with an active Lantus prescription from another state can transfer it to a WV-licensed pharmacy. West Virginia follows the standard retail pharmacy transfer rules: a non-controlled prescription may be transferred once between pharmacies in different states, as long as the original pharmacy cancels the prescription and the receiving pharmacy records the transfer. The receiving pharmacist in WV must verify the original prescriber's DEA/NPI and confirm the prescription is not expired (most insulin prescriptions are written for one year with up to 12 refills).

If the original prescription has been fully dispensed, the patient needs a new prescription from a WV-licensed provider. A telehealth visit is the fastest pathway for that, as described above.

Patients whose previous prescriber was in a different state cannot have that out-of-state provider call in refills to a West Virginia pharmacy without that provider holding a WV medical license. This is the most common bottleneck for new residents [7].

Dosing, Titration, and Clinical Monitoring After Starting

Insulin glargine is injected subcutaneously once daily, at the same time each day. The injection site should be rotated among the abdomen, thigh, and upper arm to prevent lipohypertrophy, which reduces insulin absorption and increases glycemic variability [14].

The ADA 2024 titration protocol for type 2 diabetes starts at 0.1-0.2 U/kg/day and increases by 2 units every 3 days, targeting a fasting glucose of 80-130 mg/dL [5]. For type 1 diabetes, basal insulin typically comprises 40-50% of total daily dose, with the remainder delivered as rapid-acting insulin at meals.

After initiation, the minimum monitoring schedule is:

• Fasting glucose daily (self-monitored or continuous glucose monitor)
• HbA1c at 3 months, then every 3-6 months once stable
• BMP at 3 months to reassess renal function
• Annual UACR and lipid panel per ADA Standards [5]

Hypoglycemia is the primary safety risk. The ORIGIN trial reported a rate of 1.00 severe hypoglycemia event per 100 patient-years in the glargine group versus 0.31 in the standard-care group (P<0.001) [4]. Patients must be counseled on recognition (shakiness, diaphoresis, confusion at glucose <70 mg/dL) and treatment (15 grams of fast-acting carbohydrate, recheck in 15 minutes).

Storage: unopened Lantus vials and pens are stored at 36-46°F (refrigerated). An in-use pen may be stored at room temperature (below 86°F) for up to 28 days. Do not freeze.

Cost Assistance and Patient Support Programs in West Virginia

Several overlapping programs can bring the monthly cost of Lantus to under $35 for most West Virginia patients regardless of insurance status.

The Sanofi Insulins Valyou Savings Program caps monthly out-of-pocket cost at $99 for patients using Lantus, Toujeo, or Admelog regardless of insurance status, with no income requirement [13]. Enrollment takes approximately 5 minutes online or by phone.

Insulin Help (insulinhelp.org), a nonprofit clearinghouse, connects West Virginia patients with manufacturer programs, state pharmaceutical assistance, and emergency supply programs. The site is updated quarterly and lists WV-specific FQHC contacts.

The West Virginia Diabetes Prevention and Control Program, operated through the WVDHHR in partnership with the CDC's National Diabetes Prevention Program, provides case management and can connect patients with pharmacy resources [3].

For patients below 200% of the federal poverty level, the Sanofi Patient Assistance Program provides Lantus at no cost with a physician's signature confirming income eligibility. Applications are processed within 10-14 business days.

Mark's Law (WV HB 4388, passed 2022) capped cost-sharing for insulin at $100 per 30-day supply for state-regulated commercial insurance plans. This cap applies to all insulin formulations including glargine. Federal plans (ERISA-governed employer plans) are not subject to this state cap.